State Street Corp Acquires 9,506 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

State Street Corp grew its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 0.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,058,898 shares of the company’s stock after acquiring an additional 9,506 shares during the quarter. State Street Corp’s holdings in Tenaya Therapeutics were worth $2,044,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Tenaya Therapeutics during the 3rd quarter worth approximately $49,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after buying an additional 7,000 shares during the period. Algert Global LLC bought a new stake in shares of Tenaya Therapeutics during the second quarter worth $74,000. Walleye Capital LLC acquired a new stake in shares of Tenaya Therapeutics during the third quarter worth $134,000. Finally, Panagora Asset Management Inc. bought a new stake in Tenaya Therapeutics in the 2nd quarter valued at $164,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA opened at $1.43 on Thursday. The stock has a market capitalization of $113.29 million, a PE ratio of -0.99 and a beta of 2.72. Tenaya Therapeutics, Inc. has a 52 week low of $0.99 and a 52 week high of $7.01. The stock has a 50 day moving average price of $2.39 and a 200 day moving average price of $2.57.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.07. As a group, research analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

TNYA has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital restated a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $17.33.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.